U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07179744) titled 'Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer' on Sept. 13, 2022.
Brief Summary: The purpose of this study is to determine whether certain patients can safely omit regional lymph node radiotherapy. These women must have hormone-sensitive, Her2-negative tumors, have 1-3 positive axillary nodes and have RecurIndex low-risk.
Study Start Date: July 06, 2022
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Recruitment Status: RECRUITING
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Published by HT Digital Content Services with permission from Health Daily Digest....